Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: JACC Heart Fail. 2020 Aug 12;8(10):834–843. doi: 10.1016/j.jchf.2020.06.008

Figure 3. Change in NT-proBNP concentration from baseline through 8 weeks post-randomization by dose of blinded study drug achieved at week 4.

Figure 3.

The reduction in the proportional change in NT-proBNP concentration (logarithmic scale) from baseline through week 8 with sacubitril/valsartan was consistent across all dose levels achieved. The model is adjusted for age, systolic blood pressure, and race. NT-proBNP, N-terminal pro-B-type natriuretic peptide.